Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint
Approval Still Expected And Differentiation Remains Intact
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.